AxoGen, Inc. to Host Surgeon Panel on Nerve Repair at American Association of Oral and Maxillofacial Surgeons Annual Meeting 2014

Share Article

Company to exhibit nerve repair technologies at Booth 644

AxoGen Logo

The AAOMS meeting is an optimal opportunity for us to engage with and provide education about our technologies to the surgeons who are actively treating or referring patients with nerve injuries.” - Jill Schiaparelli, SVP, AxoGen

A xoGen, Inc. (NASDAQ: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, today announced that it will sponsor a panel discussion at the 96th Annual Meeting of the American Association of Oral and Maxillofacial Surgeons (AAOMS), taking place this week in Honolulu, HI. The Company will also demonstrate its full portfolio of nerve repair products during the clinical conference at Booth 644.

The Panel, “Innovative Treatment Options for Trigeminal Nerve Injuries,” will be held on Wednesday, September 10, 2014 from 7:30 – 9:00am HAST. Presentations will include an overview of the science of nerve repair and case studies utilizing AxoGen’s Avance® Nerve Graft, AxoGuard® Nerve Protector, and AxoGuard® Nerve Connector to repair damage to the trigeminal nerve.

The panel will be moderated by John Zuniga, DMD, MS, PhD, Professor and Chairman of OMFS, University of Texas Southwest Medical Center. Dr. Zuniga will be joined by panelists Michael Miloro, DMD, MD, FACS, Professor and Department Head of OMFS, University of Illinois and Shahrokh Bagheri, DMD, MD, FACS, FICD, Chief of OMFS, Northside Hospital.

“The severity of trigeminal nerve injuries as well as the negative effects on patients are often underestimated. Patients with trigeminal nerve injuries can suffer from pain, discomfort and loss of sensation in the mouth. AxoGen’s portfolio of nerve repair products allows us to offer treatment options to these patients and help to restore their quality of life,” said Dr. Zuniga.

Jill Schiaparelli, Senior Vice President at AxoGen, added, “Every year patients undergoing routine dental procedures such as wisdom tooth extraction and dental implants may suffer from an injury to their trigeminal nerve. The AAOMS meeting is an optimal opportunity for us to engage with and provide education about our technologies to the surgeons who are actively treating or referring patients with nerve injuries.”

About the Trigeminal Nerve
The trigeminal nerve is a peripheral nerve responsible for sensation in the mouth and taste. A common cause of damage to the trigeminal nerve is the extraction of third molars (wisdom teeth) and injury caused by the placement of dental implants. The trigeminal nerve can also be injured due to certain jaw alignment and tumor removal surgeries as well as by trauma to the face.

About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development and product potential. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lee Robert "Bob" Johnston Jr, CFO
AxoGen, Inc.
+1 386.462.6856
Email >
Visit website